Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 208 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma Patient Guide in Prostate Cancer Now Available in Vietnamese One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides Protection Against HPV16 or HPV18 Infection and Is Not Inferior To Two Doses MOST POPULAR Monoclonal Antibodies May Lower Recurrence Risk for Some Early Stage Breast... February 2, 2022 Erdafitinib Prolongs Survival in Patients with Metastatic Urothelial Carcinoma and FGFR... November 3, 2023 Truck Driver Saves People From Bus Fire On Christmas Eve December 31, 2021 p53 Mutations May Differentially Affect Survival of Patients with mCRC Based... December 3, 2021 Load more HOT NEWS Breast Cancer Survivor Driven from Her Home by Noxious Gases from... FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple... Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... “World’s Tiniest Baby” Has Been Released From The Hospital
